Stay updated on Lumasiran in Primary Hyperoxaluria Type 1 Infants/Young Children Clinical Trial
Sign up to get notified when there's something new on the Lumasiran in Primary Hyperoxaluria Type 1 Infants/Young Children Clinical Trial page.

Latest updates to the Lumasiran in Primary Hyperoxaluria Type 1 Infants/Young Children Clinical Trial page
- Check2 days agoChange DetectedThe ClinicalTrials.gov site revision changed from v3.8.0 to v3.8.1.SummaryDifference0.1%

- Check9 days agoChange DetectedThe page now presents the ClinicalTrials.gov record for a terminated trial of pembrolizumab, exemestane, and leuprolide for premenopausal patients with advanced breast cancer. It includes study eligibility, treatment details, outcomes, and record dates.SummaryDifference43%

- Check16 days agoChange DetectedThe footer's displayed site revision changes from v3.7.2 to v3.8.0, while the page continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check30 days agoChange DetectedAn NIH-wide notice about the transition from “Artificial Intelligence” to “Super Intelligence” appears above the site navigation. The site revision identifier changes from v3.7.1 to v3.7.2.SummaryDifference1%

- Check37 days agoChange DetectedThe footer’s site revision identifier changes from v3.7.0 to v3.7.1 while the page continues to display a 403 error.SummaryDifference0.2%

- Check58 days agoChange DetectedThe page now displays a 403 Forbidden error with the site chrome (header/footer) instead of the study details; this indicates an access/permissions issue rather than a new feature or data update.SummaryDifference17%

Stay in the know with updates to Lumasiran in Primary Hyperoxaluria Type 1 Infants/Young Children Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lumasiran in Primary Hyperoxaluria Type 1 Infants/Young Children Clinical Trial page.